The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway

Neuroscience

Volumn 164, Issue 2, 2009, Pages 360-369

  Mabrouk, O S ^a   Marti, M ^a   Salvadori, S ^a   Morari, M ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

6 OHDA; delta opioid; microdialysis; naltrindole; Parkinson's disease; UFP 512

Indexed keywords

DOPAMINE RECEPTOR; GLUTAMIC ACID; MU OPIATE RECEPTOR AGONIST; NALTRINDOLE; OXIDOPAMINE; UFP 512; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID BRAIN LEVEL; 4 AMINOBUTYRIC ACID RELEASE; AKINESIA; AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; GABAERGIC SYSTEM; GLOBUS PALLIDUS; LOCOMOTION; MALE; MOTOR CONTROL; NERVE CELL NETWORK; NEUROTRANSMISSION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; ROTAROD TEST; SUBSTANTIA NIGRA; THALAMUS;

AMINO ACIDS; ANIMALS; ANTIPARKINSON AGENTS; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; GLUTAMIC ACID; MALE; MOTOR ACTIVITY; NALTREXONE; NARCOTIC ANTAGONISTS; NEURAL PATHWAYS; OLIGOPEPTIDES; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; SUBSTANTIA NIGRA; THALAMUS;

EID: 70349733399     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.08.058     Document Type: Article

References (47)

1. Abou-Khalil B., Young A.B., and Penney J.B. Evidence for the presynaptic localization of opiate binding sites on striatal efferent fibers. Brain Res 323 (1984) 21-29
2. Aguila B., Coulbault L., Boulouard M., Léveillé F., Davis A., Tóth G., Borsodi A., Balboni G., Salvadori S., Jauzac P., and Allouche S. In vitro and in vivo pharmacological profile of UFP-512 a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance. Br J Pharmacol 152 (2007) 1312-1324
3. Balboni G., Guerrini R., Salvadori S., Tomatis R., Bryant S.D., Bianchi C., Attila M., and Lazarus L.H. Opioid diketopiperazines: synthesis and activity of a prototypic class of opioid antagonists. Biol Chem 379 (1997) 19-29
4. Balboni G., Fiorini S., Baldisserotto A., Trapella C., Sasaki Y., Ambo A., Marczak E.D., Lazarus L.H., and Salvadori S. Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem 51 (2008) 5109-5117
5. Bezard E., Ravenscroft P., Gross C.E., Crossman A.R., and Brotchie J.M. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys. Neurobiol Dis 8 (2001) 343-350
6. Bilsky E.J., Calderon S.N., Wang T., Bernstein R.N., Davis P., Hruby V.J., McNutt R.W., Rothman R.B., Rice K.C., and Porreca F. SNC 80 a selective, nonpeptidic and systemically active opioid delta agonist. J Pharmacol Exp Ther 273 (1995) 359-366
7. Cahill C.M., McClellan K.A., Morinville A., Hoffert C., Hubatsch D., O'Donnell D., and Beaudet A. Immunohistochemical distribution of delta opioid receptors in the rat central nervous system: evidence for somatodendritic labeling and antigen-specific cellular compartmentalization. J Comp Neurol 440 (2001) 65-84
8. Chevalier G., and Deniau J.M. Inhibitory nigral influence on cerebellar evoked responses in the rat ventromedial thalamic nucleus. Exp Brain Res 48 (1982) 369-376
9. Deniau J.M., and Chevalier G. Disinhibition as a basic process in the expression of striatal functions. II. The striato-nigral influence on thalamocortical cells of the ventromedial thalamic nucleus. Brain Res 334 (1985) 227-233
10. Dewar D., Jenner P., and Marsden C.D. Effects of opioid agonist drugs on the in vitro release of 3H-GABA 3H-dopamine and 3H-5HT from slices of rat globus pallidus. Biochem Pharmacol 36 (1987) 1738-1741
11. Gerfen C.R., and Young III W.S. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res 460 (1988) 161-167
12. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma Jr. F.J., and Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
13. Henry B., Fox S.H., Crossman A.R., and Brotchie J.M. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol 171 (2001) 139-146
14. Hill M.P., Hille C.J., and Brotchie J.M. δ-opioid receptor agonists as a therapeutic approach in Parkinson's disease. Drug News Perspect 13 (2000) 261-268
15. Hille C.J., Fox S.H., Maneuf Y.P., Crossman A.R., and Brotchie J.M. Antiparkinsonian action of a δ opioid agonist in rodent and primate models of Parkinson's disease. Exp Neurol 172 (2001) 189-198
16. Klockgether T., Schwartz M., Turski L., and Sontag K.H. The rat ventromedial thalamus nucleus and motor control: role of N-methyl-D-aspartate-mediated excitation GABAergic inhibition, and muscarinic transmission. J Neurosci 6 (1986) 1702-1711
17. Kuschinski K., and Hornykiewicz O. Morphine catalepsy in the rat: relation to striatal dopamine metabolism. Eur J Pharmacol 19 (1972) 119-122
18. Llorens-Cortes C., Javoy-Agid F., Agid Y., Taquet H., and Schwartz J.C. Enkephalinergic markers in substantia nigra and caudate nucleus from Parkinsonian subjects. J Neurochem 43 (1984) 874-877
19. Mabrouk O.S., Volta M., Marti M., and Morari M. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats. New insights into the role of delta receptors in parkinsonism. J Neurochem 107 (2008) 1647-1659
20. Maneuf Y.P., Mitchell I.J., Crossman A.R., and Brotchie J.M. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol 125 (1994) 65-71
21. Mansour A., Fox C.A., Akil H., and Watson S.J. Opioid receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18 (1995) 22-29
22. Mark K.A., Soghomonian J.J., and Yamamoto B.K. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci 24 (2004) 11449-11456
23. Marsden B.J., Nguyen T.M., and Schiller P.W. Spontaneous degradation via diketopiperazine formation of peptides containing a tetrahydroisoquinoline-3-carboxylic acid residue in the 2-position of the peptide sequence. Int J Pept Protein Res 41 (1993) 313-316
24. Marti M., Mela F., Bianchi C., Beani L., and Morari M. Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors. J Neurochem 83 (2002) 635-644
25. Marti M., Mela F., Veronesi C., Guerrini R., Salvadori S., Federici M., Mercuri N.B., Rizzi A., Franchi G., Beani L., Bianchi C., and Morari M. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci 24 (2004) 6659-6666
26. Marti M., Mela F., Fantin M., Zucchini S., Brown J.M., Witta J., Di Benedetto M., Buzas B., Reinscheid R.K., Salvadori S., Guerrini R., Romualdi P., Candeletti S., Simonato M., Cox B.M., and Morari M. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci 25 (2005) 9591-9601
27. Marti M., Trapella C., Viaro R., and Morari M. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci 27 (2007) 1297-1307
28. Marti M., Trapella C., and Morari M. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA. J Neurochem 107 (2008) 1683-1696
29. McCormick S.E., and Stoessl A.J. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience 112 (2002) 851-859
30. McFarland N.R., and Haber S.N. Thalamic relay nuclei of the basal ganglia form both reciprocal and nonreciprocal cortical connections, linking multiple frontal cortical areas. J Neurosci 22 (2002) 8817-8832
31. Nisenbaum L.K., Crowley W.R., and Kitai S.T. Partial striatal dopamine depletion differentially affects striatal substance P and enkephalin messenger RNA expression. Brain Res Mol Brain Res 37 (1996) 209-216
32. Nyitrai G., Kovács I., Szárics E., Skuban N., Juhász G., and Kardos J. Role of intracellular Ca(2+) stores shaping normal activity in brain. J Neurosci Res 57 (1999) 906-915
33. Parent A., and Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 20 (1995) 91-127
34. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1982), Academic Press, Sydney, Australia
35. Pinna A., and Di Chiara G. Dopamine-dependent behavioural stimulation by non-peptide delta opioids BW 373U86 and SNC 80. 3. Facilitation of D1 and D2 responses in unilaterally 6-hydroxydopamine-lesioned rats. Behav Pharmacol 9 (1998) 15-21
36. Rick C.E., and Lacey M.G. Rat substantia nigra pars reticulata neurones are tonically inhibited via GABAA, but not GABAB, receptors in vitro. Brain Res 659 (1994) 133-137
37. Rinne U.K., Rinne J.K., Rinne J.O., Laakso K., Tenovuo O., Lönnberg P., and Koskinen V. Brain enkephalin receptors in Parkinson's disease. J Neural Transm Suppl 19 (1983) 163-171
38. Rozas G., Guerra M.J., and Labandeira-García J.L. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 2 (1997) 75-84
39. Samadi P., Bédard P.J., and Rouillard C. Opioids and motor complications in Parkinson's disease. Trends Pharmacol Sci 27 (2006) 512-517
40. Sanberg P.R., Bunsey M.D., Giordano M., and Norman A.B. The catalepsy test: its ups and downs. Behav Neurosci 102 (1988) 748-759
41. Schallert T., De Ryck M., Whishaw I.Q., Ramirez V.D., and Teitelbaum P. Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism. Exp Neurol 64 (1979) 33-43
42. Stanford I.M., and Cooper A.J. Presynaptic mu and delta opioid receptor modulation of GABAA IPSCs in the rat globus pallidus in vitro. J Neurosci 19 (1999) 4796-4803
43. Steiner H., and Gerfen C.R. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior [Review]. Exp Brain Res 123 (1998) 60-76
44. Timmerman W., and Westerink B.H. Electrical stimulation of the substantia nigra reticulata: detection of neuronal extracellular GABA in the ventromedial thalamus and its regulatory mechanism using microdialysis in awake rats. Synapse 26 (1997) 62-71
45. Ungerstedt U., and Arbuthnott G.W. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 24 (1970) 485-493
46. Varga E.V., Navratilova E., Stropova D., Jambrosic J., Roeske W.R., and Yamamura H.I. Agonist-specific regulation of the delta-opioid receptor. Life Sci 76 (2004) 599-612
47. Vergura R., Balboni G., Spagnolo B., Gavioli E., Lambert D.G., McDonald J., Trapella C., Lazarus L.H., Regoli D., Guerrini R., Salvadori S., and Caló G. Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512) a novel selective delta opioid receptor agonist. Peptides 29 (2007) 93-103